Managing the Syndrome: Treatment Strategies for Hb Lepore
At a Glance
Hb Lepore treatment depends on how severely the condition affects blood production: some people need regular transfusions, while others need them only during major stress. Medicines, stem cell transplant, and gene therapy may be considered for selected patients at specialist centers.
Because Hemoglobin Lepore (Hb Lepore) behaves clinically like beta-thalassemia, hematologists manage it based on your phenotype—a medical term for how the condition actually affects your body, regardless of your specific genetics [1][2]. Treatment is generally split into two individualized pathways: Transfusion-Dependent Thalassemia (TDT) and Non-Transfusion-Dependent Thalassemia (NTDT).
Important: Do not start, stop, or change the frequency of your transfusions or chelation therapy based on this guide. All decisions must be made directly with your hematology team.
The Foundation: Transfusion Strategy
For those with a severe Hb Lepore phenotype, regular blood transfusions are the primary way to provide your body with the healthy red blood cells it cannot make itself.
- Transfusion-Dependent (TDT): If you are in this category, you require regular, scheduled transfusions to survive and thrive. A common pre-transfusion hemoglobin target is approximately 9 to 10.5 g/dL to suppress ineffective red blood cell production, but your specific target and interval will be individualized based on your symptoms, growth, marrow expansion, and any complications [3][4].
- Non-Transfusion-Dependent (NTDT): You may only need blood during specific “stress” events, such as a major infection or pregnancy [5]. However, NTDT does not mean transfusions are permanently off the table; your doctor may recommend starting regular transfusions if you develop severe complications, significant bone changes, or pulmonary hypertension [6].
Medical Therapies
Beyond transfusions, several medications are used in the broader beta-thalassemia population, though evidence specifically for Hb Lepore is often limited and requires specialist extrapolation.
- Luspatercept: This is an injectable medication approved in many jurisdictions for adults with beta-thalassemia. In the pivotal BELIEVE trial for transfusion-dependent patients, roughly 21% of those taking luspatercept achieved the strict goal of reducing their transfusion burden by at least 33% over a sustained period, compared to 4.5% on placebo [7][8]. It carries important risks, including high blood pressure (hypertension), bone pain, and a risk of blood clots (thromboembolic events), and has specific pregnancy restrictions [9].
- Hydroxyurea: This oral medication is sometimes used in an attempt to help the body produce more fetal hemoglobin (HbF). Evidence for its use in Hb Lepore is variable and limited. Because it can cause dangerous drops in white blood cells and platelets (cytopenias), any use must be closely directed by a specialist with frequent blood count monitoring [10][11].
Potentially Curative and Disease-Modifying Options
For selected patients, there are intensive paths that aim to fundamentally alter how the body produces blood.
- Stem Cell Transplant (HSCT): This involves replacing your bone marrow with healthy cells from a matched donor (usually a sibling). It is most successful when done in childhood before severe iron-related organ damage occurs [12][13]. However, it carries significant, potentially life-threatening risks, including Graft-versus-Host Disease (GVHD) and severe infections [14][15].
- Gene Therapy: Advanced therapies like betibeglogene autotemcel (Zynteglo) and exagamglogene autotemcel (Casgevy) are FDA-approved for specified ages of transfusion-dependent beta-thalassemia [16][17]. They work differently: Zynteglo adds a modified beta-globin gene to your cells, while Casgevy uses gene editing on the BCL11A pathway to force your body to make more fetal hemoglobin. Both require intense, myeloablative chemotherapy “conditioning” beforehand, which carries serious risks including prolonged hospitalization, severe infections, and a high risk of permanent infertility [18][17]. Furthermore, eligibility and evidence specifically for the Hb Lepore variant must be confirmed at a highly specialized center.
Because Hb Lepore is rare, your care team will use broad thalassemia guidelines combined with a deep understanding of your unique clinical picture to tailor a safe and effective plan [2][18].
Common questions in this guide
How is a treatment plan for Hb Lepore chosen?
When does Hb Lepore require regular blood transfusions?
Can medicines reduce the need for transfusions in Hb Lepore?
What are the risks of a stem cell transplant or gene therapy for Hb Lepore?
How is iron overload monitored during Hb Lepore treatment?
Can someone with non-transfusion-dependent Hb Lepore later need regular transfusions?
Get notified when new evidence is published on Hemoglobin Lepore-beta-thalassemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD, Motta I
Hematology. American Society of Hematology. Education Program 2017; (2017(1)):278-283 doi:10.1182/asheducation-2017.1.278.
PMID: 29222267 - 2
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.
Farmakis D, Porter J, Taher A, et al.
HemaSphere 2022; (6(8)):e732 doi:10.1097/HS9.0000000000000732.
PMID: 35928543 - 3
Novel Red Blood Cell Exchange Parameters for Treatment of Transfusion-Dependent Thalassemia Based on Experience of Five Patients.
Sevcik K, Jackson C, Williams SM, et al.
Journal of hematology 2025; (14(4)):210-213 doi:10.14740/jh2086.
PMID: 40904934 - 4
Challenges of blood transfusions in β-thalassemia.
Shah FT, Sayani F, Trompeter S, et al.
Blood reviews 2019; (37()):100588 doi:10.1016/j.blre.2019.100588.
PMID: 31324412 - 5
Morbidities in non-transfusion-dependent thalassemia.
Saliba AN, Taher AT
Annals of the New York Academy of Sciences 2016; (1368(1)):82-94 doi:10.1111/nyas.13083.
PMID: 27186941 - 6
Thalassemia: Common Clinical Queries in Management.
Lal A, Bansal D
Indian journal of pediatrics 2020; (87(1)):75-81 doi:10.1007/s12098-019-03065-5.
PMID: 31620986 - 7
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, et al.
The New England journal of medicine 2020; (382(13)):1219-1231 doi:10.1056/NEJMoa1910182.
PMID: 32212518 - 8
The use of luspatercept for thalassemia in adults.
Cappellini MD, Taher AT
Blood advances 2021; (5(1)):326-333 doi:10.1182/bloodadvances.2020002725.
PMID: 33570654 - 9
Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
Musallam KM, Taher AT, Kattamis A, et al.
Drug design, development and therapy 2023; (17()):1583-1591 doi:10.2147/DDDT.S368584.
PMID: 37255740 - 10
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.
Yasara N, Wickramarathne N, Mettananda C, et al.
Scientific reports 2022; (12(1)):2752 doi:10.1038/s41598-022-06774-8.
PMID: 35177777 - 11
Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
Algiraigri AH, Wright NAM, Paolucci EO, Kassam A
Pediatric hematology and oncology 2017; (34(8)):435-448 doi:10.1080/08880018.2017.1354948.
PMID: 29337597 - 12
Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.
Testa U, Castelli G, Pelosi E
Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041379.
PMID: 41753067 - 13
Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010.
Baronciani D, Angelucci E, Potschger U, et al.
Bone marrow transplantation 2016; (51(4)):536-41 doi:10.1038/bmt.2015.293.
PMID: 26752139 - 14
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.
Caocci G, Orofino MG, Vacca A, et al.
American journal of hematology 2017; (92(12)):1303-1310 doi:10.1002/ajh.24898.
PMID: 28850704 - 15
A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia.
Liu R, Xiao H, Qin C, et al.
Nature communications 2026; (17(1)).
PMID: 41730859 - 16
Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.
Inam Z, Han H, Webb J, Delaney M
Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.
PMID: 41223813 - 17
Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel.
Mirza A, Ritsert ML, Tao G, et al.
Blood advances 2025; (9(1)):29-38 doi:10.1182/bloodadvances.2024014104.
PMID: 39418614 - 18
Current therapeutic landscape of β-thalassemia: focus on gene therapy.
Cheng AN, Kwiatkowski JL
Therapeutic advances in rare disease 2026; (7()):26330040261433028 doi:10.1177/26330040261433028.
PMID: 41919270
This page provides general information about Hb Lepore treatment and does not constitute medical advice. Your hematology team should guide decisions about transfusions, medicines, iron chelation, transplant, or gene therapy for your specific situation.